Donald E Mager

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4716601/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Systems model identifies baseline cytokine concentrations as potential predictors of rheumatoid arthritis inflammatory response to biologics. British Journal of Pharmacology, 2022, 179, 4063-4077.	5.4	4
2	Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses. Science Translational Medicine, 2022, 14, eabg8402.	12.4	28
3	Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation. Journal of Pharmacology and Experimental Therapeutics, 2021, 377, 370-384.	2.5	5
4	Population Pharmacokinetic Model of N-acetylmannosamine (ManNAc) and N-acetylneuraminic acid (Neu5Ac) in Subjects with GNE Myopathy. Drugs in R and D, 2021, 21, 189-202.	2.2	5
5	Network-Based Systems Analysis Explains Sequence-Dependent Synergism of Bortezomib and Vorinostat in Multiple Myeloma. AAPS Journal, 2021, 23, 101.	4.4	2
6	Cluster Gauss–Newton and CellNOpt Parameter Estimation in a Small Protein Signaling Network of Vorinostat and Bortezomib Pharmacodynamics. AAPS Journal, 2021, 23, 110.	4.4	3
7	Platelet Transfusions Can Increase or Decrease the Inflammatory Response and Mortality in a Murine Model of Neonatal Polymicrobial Sepsis. Blood, 2021, 138, 2147-2147.	1.4	1
8	Systems Pharmacology Modeling Identifies a Novel Treatment Strategy for Bortezomib-Induced Neuropathic Pain. Frontiers in Pharmacology, 2021, 12, 817236.	3.5	6
9	Pharmacometrics and Systems Pharmacology 2030. Clinical Pharmacology and Therapeutics, 2020, 107, 76-78.	4.7	18
10	Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactionsÂin pancreatic cancer cells. BMC Cancer, 2020, 20, 1024.	2.6	3
11	Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer. British Journal of Cancer, 2020, 123, 1502-1512.	6.4	14
12	Population-based meta-analysis of bortezomib exposure–response relationships in multiple myeloma patients. Journal of Pharmacokinetics and Pharmacodynamics, 2020, 47, 77-90.	1.8	4
13	Rituximab dosing in hematological malignancies: an old question, revisited. Cancer Chemotherapy and Pharmacology, 2019, 84, 661-666.	2.3	2
14	Pharmacodynamic Drug–Drug Interactions. Clinical Pharmacology and Therapeutics, 2019, 105, 1395-1406.	4.7	101
15	Systems Modeling of Bortezomib and Dexamethasone Combinatorial Effects on Bone Homeostasis in Multiple Myeloma Patients. Journal of Pharmaceutical Sciences, 2019, 108, 732-740.	3.3	4
16	The impact of tacrolimus exposure on extrarenal adverse effects in adult renal transplant recipients. British Journal of Clinical Pharmacology, 2019, 85, 516-529.	2.4	20
17	Machine Learning Models for the Prediction of Chemotherapy-Induced Peripheral Neuropathy. Pharmaceutical Research, 2019, 36, 35.	3.5	17
18	Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities?. Journal of Clinical Pharmacology, 2019, 59, 309-325.	2.0	50

#	Article	IF	CITATIONS
19	Pharmacodynamic Models of Differential Bortezomib Signaling Across Several Cell Lines of Multiple Myeloma. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 146-157.	2.5	5
20	Fifty-Eight Years and Counting: High-Impact Publishing in Computational Pharmaceutical Sciences and Mechanism-Based Modeling. Journal of Pharmaceutical Sciences, 2019, 108, 2-7.	3.3	4
21	Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity. Clinical Cancer Research, 2018, 24, 2631-2641.	7.0	52
22	Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 734-751.	2.5	9
23	Boolean network modeling in systems pharmacology. Journal of Pharmacokinetics and Pharmacodynamics, 2018, 45, 159-180.	1.8	60
24	Tacrolimus Population Pharmacokinetics and Multiple <i>CYP3A5</i> Genotypes in Black and White Renal Transplant Recipients. Journal of Clinical Pharmacology, 2018, 58, 1184-1195.	2.0	34
25	Population Pharmacokinetic (PK)/Pharmacodynamic (PD) Modeling of Myelosuppression in Patients with Hematologic Malignancies for CPX-351 and Standard-of-Care 7+3 Therapy. Blood, 2018, 132, 4037-4037.	1.4	Ο
26	Sequential Exposure of Bortezomib and Vorinostat is Synergistic in Multiple Myeloma Cells. Pharmaceutical Research, 2017, 34, 668-679.	3.5	12
27	Modelâ€Based Evaluation of Exenatide Effects on the QT Interval in Healthy Subjects Following Continuous IV Infusion. Journal of Clinical Pharmacology, 2017, 57, 956-965.	2.0	2
28	Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration. AAPS Journal, 2017, 19, 487-496.	4.4	13
29	Quantitative systems toxicology. Current Opinion in Toxicology, 2017, 4, 79-87.	5.0	32
30	Cell Signaling Model Connects Vorinostat Pharmacokinetics and Tumor Growth Response in Multiple Myeloma Xenografts. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 756-764.	2.5	6
31	Influence of Meals and Glycemic Changes on QT Interval Dynamics. Journal of Clinical Pharmacology, 2017, 57, 966-976.	2.0	19
32	A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates. AAPS Journal, 2017, 19, 1436-1448.	4.4	17
33	Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity. MAbs, 2017, 9, 15-28.	5.2	11
34	Population pharmacokinetics of exenatide. British Journal of Clinical Pharmacology, 2017, 83, 517-526.	2.4	22
35	Systems Pharmacology and Pharmacodynamics: An Introduction. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 3-14.	0.6	4
36	Calculated Log D Is Inversely Correlated With Select Camptothecin Clearance and Efficacy in Colon Cancer Xenografts. Journal of Pharmaceutical Sciences, 2016, 105, 1561-1566.	3.3	2

#	Article	IF	CITATIONS
37	Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the the the the the the the the the th	12.0	4
38	Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of antiâ€factor VIII antibodies in hemophilia A mice. Biopharmaceutics and Drug Disposition, 2016, 37, 409-420.	1.9	4
39	Physiologically-Based Pharmacokinetic-Pharmacodynamic Modeling of 1Â,25-Dihydroxyvitamin D3 in Mice. Drug Metabolism and Disposition, 2016, 44, 189-208.	3.3	13
40	Effects of hypertonic buffer composition on lymph node uptake and bioavailability of rituximab, after subcutaneous administration. Biopharmaceutics and Drug Disposition, 2015, 36, 115-125.	1.9	21
41	<pre><scp>PKPD</scp> modelling to predict altered disposition of 1î±,25â€dihydroxyvitamin <scp>D</scp>₃ in mice due to doseâ€dependent regulation of <scp>CYP27B1</scp> on synthesis and <scp>CYP24A1</scp> on degradation. British Journal of Pharmacology, 2015, 172, 3611-3626.</pre>	5.4	6
42	Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients. Cancer Chemotherapy and Pharmacology, 2015, 76, 85-96.	2.3	14
43	The American Conference on Pharmacometrics 2015 (ACoP6). Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42, 1-2.	1.8	1
44	Soy Phosphatidylinositol Containing Nanoparticle Prolongs Hemostatic Activity of B-Domain Deleted Factor VIII in Hemophilia A Mice. Journal of Pharmaceutical Sciences, 2015, 104, 388-395.	3.3	13
45	Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice. Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42, 541-552.	1.8	24
46	Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells. Journal of Pharmacology and Experimental Therapeutics, 2015, 354, 448-458.	2.5	25
47	Mathematical model of platelet turnover in thrombocytopenic and nonthrombocytopenic preterm neonates. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H68-H73.	3.2	6
48	Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration. Cancer Chemotherapy and Pharmacology, 2015, 75, 67-75.	2.3	13
49	Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology. Pharmaceutics, 2014, 6, 137-174.	4.5	81
50	Dual Physiologically Based Pharmacokinetic Model of Liposomal and Nonliposomal Amphotericin B Disposition. Pharmaceutical Research, 2014, 31, 35-45.	3.5	37
51	Interspecies Pharmacokinetic Modeling of Subcutaneous Absorption of Rituximab in Mice and Rats. Pharmaceutical Research, 2014, 31, 3265-3273.	3.5	24
52	Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice. Biopharmaceutics and Drug Disposition, 2014, 35, 154-163.	1.9	7
53	Populationâ€based metaâ€analysis of furosemide pharmacokinetics. Biopharmaceutics and Drug Disposition, 2014, 35, 119-133	1.9	15
54	Pharmacokinetic and Pharmacodynamic Analysis of Inosine Monophosphate Dehydrogenase Activity in Hematopoietic Cell Transplantation Recipients Treated with Mycophenolate Mofetil. Biology of Blood and Marrow Transplantation, 2014, 20, 1121-1129.	2.0	21

#	Article	IF	CITATIONS
55	Expansion of the neonatal platelet mass is achieved via an extension of platelet lifespan. Blood, 2014, 123, 3381-3389.	1.4	58
56	Population Pharmacodynamic Modeling of Hyperglycemic Clamp and Meal Tolerance Tests in Patients with Type 2 Diabetes Mellitus. AAPS Journal, 2013, 15, 1051-1063.	4.4	1
57	Network-Based Approaches in Drug Discovery and Early Development. Clinical Pharmacology and Therapeutics, 2013, 94, 651-658.	4.7	82
58	Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis. Biopharmaceutics and Drug Disposition, 2013, 34, 336-347.	1.9	8
59	Mechanisms of Subcutaneous Absorption of Rituximab in Rats. Drug Metabolism and Disposition, 2013, 41, 248-255.	3.3	41
60	Nonrelapse Mortality and Mycophenolic Acid Exposure in Nonmyeloablative Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1159-1166.	2.0	29
61	Interspecies Modeling and Prediction of Human Exenatide Pharmacokinetics. Pharmaceutical Research, 2013, 30, 751-760.	3.5	29
62	Systems Pharmacological Analysis of Paclitaxel-Mediated Tumor Priming That Enhances Nanocarrier Deposition and Efficacy. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 103-112.	2.5	27
63	Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy- <i>N,N</i> -Dimethyltryptamine, and the Impact of CYP2D6 Status. Drug Metabolism and Disposition, 2013, 41, 975-986.	3.3	24
64	Populationâ€based metaâ€analysis of hydrochlorothiazide pharmacokinetics. Biopharmaceutics and Drug Disposition, 2013, 34, 527-539.	1.9	17
65	Population Pharmacodynamic Modeling of Exenatide After 2-Week Treatment in STZ/NA Diabetic Rats. Journal of Pharmaceutical Sciences, 2013, 102, 3844-3851.	3.3	13
66	Allometry of Factor VIII and Informed Scaling of Next-Generation Therapeutic Proteins. Journal of Pharmaceutical Sciences, 2013, 102, 2380-2394.	3.3	7
67	Dynamic Model of Platelet Lifespan in Adult and Newborn Mice. FASEB Journal, 2013, 27, lb535.	0.5	0
68	Combinatorial Chemotherapeutic Efficacy in Non-Hodgkin Lymphoma Can Be Predicted by a Signaling Model of CD20 Pharmacodynamics. Cancer Research, 2012, 72, 1632-1641.	0.9	30
69	A Limited Sampling Schedule to Estimate Mycophenolic Acid Area Under the Concentrationâ€īme Curve in Hematopoietic Cell Transplantation Recipients. Journal of Clinical Pharmacology, 2012, 52, 1654-1664.	2.0	17
70	Merging Systems Biology with Pharmacodynamics. Science Translational Medicine, 2012, 4, 126ps7.	12.4	138
71	Meta-analysis of Nanoparticulate Paclitaxel Delivery System Pharmacokinetics and Model Prediction of Associated Neutropenia. Pharmaceutical Research, 2012, 29, 2833-2844.	3.5	22
72	Physiologically Based Pharmacokinetic Model for Composite Nanodevices: Effect of Charge and Size on In Vivo Disposition. Pharmaceutical Research, 2012, 29, 2534-2542.	3.5	38

#	Article	IF	CITATIONS
73	Pharmacokinetics and Pharmacodynamics of Anti-BR3 Monoclonal Antibody in Mice. Pharmaceutical Research, 2012, 29, 3180-3187.	3.5	1
74	Mechanisms of Tumor Vascular Priming by a Nanoparticulate Doxorubicin Formulation. Pharmaceutical Research, 2012, 29, 3312-3324.	3.5	14
75	Semi-mechanistic Population Pharmacokinetic Model of Multivalent Trastuzumab Emtansine in Patients with Metastatic Breast Cancer. Clinical Pharmacology and Therapeutics, 2012, 92, 520-527.	4.7	42
76	Population Pharmacokinetic Model for a Novel Oral Hypoglycemic Formed In Vivo: Comparing the Use of Active Metabolite Data Alone Versus Using Data of Upstream and Downstream Metabolites. Journal of Clinical Pharmacology, 2012, 52, 404-415.	2.0	2
77	Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatmentâ€resistant bipolar depression. British Journal of Clinical Pharmacology, 2012, 74, 304-314.	2.4	109
78	Subcutaneous Absorption of Monoclonal Antibodies: Role of Dose, Site of Injection, and Injection Volume on Rituximab Pharmacokinetics in Rats. Pharmaceutical Research, 2012, 29, 490-499.	3.5	82
79	Application of Pharmacokinetic/Pharmacodynamic Modeling in the Development of Antibody-Based Therapeutics. , 2012, , 285-302.		2
80	Quantitative structure–pharmacokinetic relationships. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 63-77.	3.3	9
81	Pharmacodynamic Model of Parathyroid Hormone Modulation by a Negative Allosteric Modulator of the Calcium-Sensing Receptor. AAPS Journal, 2011, 13, 265-273.	4.4	9
82	Physiologically Based Pharmacokinetic Model of Amphotericin B Disposition in Rats Following Administration of Deoxycholate Formulation (Fungizone®): Pooled Analysis of Published Data. AAPS Journal, 2011, 13, 255-64.	4.4	23
83	Impact of dose selection on parameter estimation using a rapid binding approximation model of target-mediated drug disposition. Journal of Pharmacokinetics and Pharmacodynamics, 2011, 38, 223-235.	1.8	2
84	Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women. Biopharmaceutics and Drug Disposition, 2011, 32, 471-481.	1.9	36
85	Enantioselective pharmacokinetics of (<i>R</i>)―and (<i>S</i>)â€ketamine after a 5â€day infusion in patients with complex regional pain syndrome. Chirality, 2011, 23, 138-143.	2.6	26
86	Immunogenicity and pharmacokinetic studies of recombinant Factor VIII containing lipid cochleates. Drug Delivery, 2011, 18, 246-254.	5.7	8
87	Comparison of Two Pharmacodynamic Transduction Models for the Analysis of Tumor Therapeutic Responses in Model Systems. AAPS Journal, 2010, 12, 1-10.	4.4	53
88	Quantitative structure–property relationships of camptothecins in humans. Cancer Chemotherapy and Pharmacology, 2010, 65, 325-333.	2.3	5
89	Selection between Michaelis–Menten and target-mediated drug disposition pharmacokinetic models. Journal of Pharmacokinetics and Pharmacodynamics, 2010, 37, 25-47.	1.8	77
90	Interspecies Scaling of Receptor-Mediated Pharmacokinetics and Pharmacodynamics of Type I Interferons. Pharmaceutical Research, 2010, 27, 920-932.	3.5	42

#	Article	IF	CITATIONS
91	Type I Interferon Receptor is a Primary Regulator of Target-Mediated Drug Disposition of Interferon-β in Mice. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 327-332.	2.5	14
92	Differential Pharmacodynamic Effects of Paclitaxel Formulations in an Intracranial Rat Brain Tumor Model. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 479-488.	2.5	17
93	Bridging Pharmacology and Pathophysiology via Systems Modeling. Journal of Clinical Pharmacology, 2010, 50, 56S-57S.	2.0	1
94	Role of P-Glycoprotein in Region-Specific Gastrointestinal Absorption of Talinolol in Rats. Drug Metabolism and Disposition, 2010, 38, 1560-1566.	3.3	34
95	Testosterone Concentrations in Diabetic and Nondiabetic Obese Men. Diabetes Care, 2010, 33, 1186-1192.	8.6	286
96	Pharmacokinetics and Toxicodynamics of Pralidoxime Effects on Paraoxon-Induced Respiratory Toxicity. Toxicological Sciences, 2010, 116, 660-672.	3.1	20
97	Pharmacodynamic profiles of ketamine (R)- and (S)- with 5-day inpatient infusion for the treatment of complex regional pain syndrome. Pain Physician, 2010, 13, 379-87.	0.4	40
98	Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Parathyroid Hormone-Calcium Homeostasis in Rats and Humans. Journal of Pharmacology and Experimental Therapeutics, 2009, 330, 169-178.	2.5	23
99	Mechanisms of interferon-Î ² effects on bone homeostasis. Biochemical Pharmacology, 2009, 77, 1757-1762.	4.4	37
100	Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model. Journal of Pharmacokinetics and Pharmacodynamics, 2009, 36, 199-219.	1.8	25
101	Quantitative Structureâ€Property Relationships Modeling to Predict In Vitro and In Vivo Binding of Drugs to the Bile Sequestrant, Colesevelam (Welchol). Journal of Clinical Pharmacology, 2009, 49, 1185-1195.	2.0	14
102	Scaling Pharmacodynamics from In Vitro and Preclinical Animal Studies to Humans. Drug Metabolism and Pharmacokinetics, 2009, 24, 16-24.	2.2	118
103	Phosphatidylserine Containing Liposomes Reduce Immunogenicity of Recombinant Human Factor VIII (rFVIII) in a Murine Model of Hemophilia A**Karthik Ramani and Razvan D. Miclea contributed equally to the manuscript Journal of Pharmaceutical Sciences, 2008, 97, 1386-1398.	3.3	49
104	Development of Translational Pharmacokinetic–Pharmacodynamic Models. Clinical Pharmacology and Therapeutics, 2008, 83, 909-912.	4.7	109
105	Pharmacokinetic/Pharmacodynamic Modeling of Renin Biomarkers in Subjects Treated With the Renin Inhibitor Aliskiren. Clinical Pharmacology and Therapeutics, 2008, 84, 136-143.	4.7	18
106	Population Exposureâ€Response Modeling of Metformin in Patients With Type 2 Diabetes Mellitus. Journal of Clinical Pharmacology, 2008, 48, 696-707.	2.0	39
107	Population Pharmacodynamic Modelling of Aspirin- and Ibuprofen-Induced Inhibition of Platelet Aggregation in Healthy Subjects. Clinical Pharmacokinetics, 2008, 47, 129-137.	3.5	37
108	Effects of Ibuprofen on the Magnitude and Duration of Aspirin's Inhibition of Platelet Aggregation: Clinical Consequences in Stroke Prophylaxis. Journal of Clinical Pharmacology, 2008, 48, 117-122.	2.0	58

#	Article	IF	CITATIONS
109	Integrated Cellular Bone Homeostasis Model for Denosumab Pharmacodynamics in Multiple Myeloma Patients. Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 555-562.	2.5	72
110	Use of Wavelet and Fast Fourier Transforms in Pharmacodynamics. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 423-430.	2.5	17
111	Analysis of Functional Signaling Domains from Fluorescence Imaging and the Two-Dimensional Continuous Wavelet Transform. Biophysical Journal, 2007, 93, 2900-2910.	0.5	11
112	HPLC–atmospheric pressure chemical ionization mass spectrometric method for enantioselective determination of R,S-propranolol and R,S-hyoscyamine in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 859, 213-221.	2.3	39
113	Partial derivative—Based sensitivity analysis of models describing target-mediated drug disposition. AAPS Journal, 2007, 9, E181-E189.	4.4	26
114	Population Pharmacokinetic/Pharmacodynamic Modeling of Systemic Corticosteroid Inhibition of Whole Blood Lymphocytes: Modeling Interoccasion Pharmacodynamic Variability. Pharmaceutical Research, 2007, 24, 1088-1097.	3.5	25
115	Quantitative structure–pharmacokinetic/pharmacodynamic relationships. Advanced Drug Delivery Reviews, 2006, 58, 1326-1356.	13.7	74
116	Target-mediated drug disposition and dynamics. Biochemical Pharmacology, 2006, 72, 1-10.	4.4	220
117	Caloric restriction and intermittent fasting alter spectral measures of heart rate and blood pressure variability in rats. FASEB Journal, 2006, 20, 631-637.	0.5	215
118	Mapping the Dose–Effect Relationship of Orbofiban from Sparse Data with an Artificial Neural Network. Journal of Pharmaceutical Sciences, 2005, 94, 2475-2486.	3.3	9
119	Pharmacokinetics and Pharmacodynamics of PEGylated IFN-? 1a Following Subcutaneous Administration in Monkeys. Pharmaceutical Research, 2005, 22, 58-61.	3.5	39
120	Quasi-Equilibrium Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition. Pharmaceutical Research, 2005, 22, 1589-1596.	3.5	190
121	Effect of Repetitive Administration of Doxorubicin-Containing Liposomes on Plasma Pharmacokinetics and Drug Biodistribution in a Rat Brain Tumor Model. Clinical Cancer Research, 2005, 11, 8856-8865.	7.0	60
122	Identification of Plasma Membrane Macro- and Microdomains from Wavelet Analysis of FRET Microscopy. Biophysical Journal, 2005, 88, 3625-3634.	0.5	9
123	EFFECTS OF PROTEIN CALORIE MALNUTRITION ON THE PHARMACOKINETICS OF KETAMINE IN RATS. Drug Metabolism and Disposition, 2004, 32, 786-793.	3.3	30
124	PHYSIOLOGICAL MODELING OF FORMULATED AND CRYSTALLINE 3,3â€2-DIINDOLYLMETHANE PHARMACOKINETICS FOLLOWING ORAL ADMINISTRATION IN MICE. Drug Metabolism and Disposition, 2004, 32, 632-638.	3.3	114
125	Exendin-4 Pharmacodynamics: Insights from the Hyperglycemic Clamp Technique. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 830-835.	2.5	24
126	Pharmacokinetics of Recombinant Human Leukemia Inhibitory Factor in Sheep. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 1085-1092.	2.5	32

#	Article	IF	CITATIONS
127	Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability. Clinical Pharmacology and Therapeutics, 2004, 75, 60-69.	4.7	14
128	Kullback-Leibler clustering of continuous wavelet transform measures of heart rate variability. Biomedical Sciences Instrumentation, 2004, 40, 337-42.	0.2	8
129	Integrated QSPR—Pharmacodynamic Model of Genomic Effects of Several Corticosteroids. Journal of Pharmaceutical Sciences, 2003, 92, 881-889.	3.3	17
130	Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. Journal of Pharmaceutical Sciences, 2003, 92, 985-994.	3.3	54
131	Relative immunosuppressive potency of therapeutic corticosteroids measured by whole blood lymphocyte proliferation. Journal of Pharmaceutical Sciences, 2003, 92, 1521-1525.	3.3	41
132	Methods of estimation of IC50 and SC50 parameters for indirect response models from single dose data. Journal of Pharmaceutical Sciences, 2003, 92, 1438-1454.	3.3	4
133	Receptor-Mediated Pharmacokinetics and Pharmacodynamics of Interferon-β1a in Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 262-270.	2.5	76
134	Simultaneous Modeling of Abciximab Plasma Concentrations and ex Vivo Pharmacodynamics in Patients Undergoing Coronary Angioplasty. Journal of Pharmacology and Experimental Therapeutics, 2003, 307, 969-976.	2.5	45
135	Dose Equivalency Evaluation of Major Corticosteroids: Pharmacokinetics and Cell Trafficking and Cortisol Dynamics. Journal of Clinical Pharmacology, 2003, 43, 1216-1227.	2.0	132
136	Diversity of Mechanism-Based Pharmacodynamic Models. Drug Metabolism and Disposition, 2003, 31, 510-518.	3.3	318
137	Quantitative Structure–Pharmacokinetic/Pharmacodynamic Relationships of Corticosteroids in Man. Journal of Pharmaceutical Sciences, 2002, 91, 2441-2451.	3.3	39
138	Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in humans. Pharmaceutical Research, 2002, 19, 1537-1543.	3.5	55
139	General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Journal of Pharmacokinetics and Pharmacodynamics, 2001, 28, 507-532.	1.8	501
140	Mechanistic Pharmacokinetic/Pharmacodynamic Models II. , 0, , 607-631.		3
141	Preclinical Pharmacokinetics. , 0, , 253-278.		1